Founder & CEO
Orhan Avur, Founder & CEO of Unibioscience, brings over a decade of experience in biotechnology and diagnostics commercialization. His background in building scalable diagnostic solutions during the global health crisis provides the technical foundation for Unibioscience's mission to bridge the gap between clinical research and accessible, at-home monitoring.
The founding team previously commercialized diagnostic solutions during the 2021–2022 period, generating €4.8M in revenue. This execution experience directly supports Unibioscience's next mission: building a platform infrastructure for recurring risk monitoring and structured follow-up.
A Human Reason to Build Earlier Risk Awareness
Our journey began with a human reminder that earlier awareness, more research, and better access matter. We are building a platform that honors that legacy by providing the tools for continuous monitoring and structured insights, ensuring that no one misses the opportunity for earlier risk awareness.
Scientific & Technical Leadership
Guided by a team of experts in biomarker science and digital health infrastructure.
Orhan Avur
Founder & CEO
With a background in biotechnology and business development, Orhan leads the transition from diagnostics execution to accessible early risk awareness.
Noreddine Aggoun, PhD
Scientific / Technical Lead
Expert in biomarker signal detection and lateral flow technology, ensuring the technical feasibility of our at-home monitoring infrastructure.
Prof. Jean-Pierre Gillet
Scientific Advisor
A leading expert in clinical validation and European regulatory pathways, providing critical guidance for our IVDR-aligned development.
Our Development Timeline
A structured path from laboratory validation to clinical readiness.
2020
Unibioscience diagnostics activity begins with foundational research into biomarker signal detection and early risk awareness.
2021–2022
COVID-19 diagnostics commercialization and €4.8M revenue generated, providing critical execution experience for the Unibioscience platform.
2023
Laboratory work on cancer risk screening concept, focusing on biomarker signal detectability and technical feasibility.
2024–2025
Belgium-based platform development, integrating AI-supported interpretation and smartphone-guided scanning workflows.
2026 Onward
Clinical validation and IVDR-aligned development, transitioning toward structured European clinical validation and regulatory approval.
The Unibioscience platform is currently in clinical development and is not approved for commercial use. It is intended to support early risk awareness and does not provide a definitive diagnosis. Any elevated-risk result should be confirmed through clinical evaluation and laboratory-based testing.